AdaptHealth Corp. $AHCO Shares Sold by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC cut its position in shares of AdaptHealth Corp. (NASDAQ:AHCO) by 83.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 20,719 shares of the company’s stock after selling 107,325 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in AdaptHealth were worth $195,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Iron Triangle Partners LP acquired a new stake in AdaptHealth in the first quarter valued at $17,496,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in AdaptHealth in the 1st quarter valued at about $4,358,000. Nuveen LLC acquired a new stake in AdaptHealth in the 1st quarter valued at about $3,427,000. Woodline Partners LP purchased a new position in AdaptHealth during the 1st quarter valued at about $2,851,000. Finally, New Age Alpha Advisors LLC acquired a new position in AdaptHealth during the first quarter worth about $2,503,000. 82.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on AHCO shares. Zacks Research lowered shares of AdaptHealth from a “hold” rating to a “strong sell” rating in a research report on Friday, September 19th. Canaccord Genuity Group upped their target price on AdaptHealth from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of AdaptHealth in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut AdaptHealth from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. Five analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, AdaptHealth presently has an average rating of “Hold” and an average price target of $13.60.

Insider Activity

In related news, Director David Solomon Williams III sold 8,200 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $9.73, for a total value of $79,786.00. Following the completion of the sale, the director directly owned 50,045 shares in the company, valued at approximately $486,937.85. The trade was a 14.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.55% of the company’s stock.

AdaptHealth Price Performance

AHCO stock opened at $9.10 on Wednesday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of 16.55, a price-to-earnings-growth ratio of 1.37 and a beta of 1.72. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 1.09. AdaptHealth Corp. has a 52-week low of $7.11 and a 52-week high of $11.63. The stock’s fifty day simple moving average is $9.21 and its 200-day simple moving average is $9.15.

AdaptHealth (NASDAQ:AHCO) last released its earnings results on Tuesday, November 4th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.05). The business had revenue of $820.31 million for the quarter, compared to analysts’ expectations of $799.62 million. AdaptHealth had a return on equity of 4.85% and a net margin of 2.53%.The business’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.15 earnings per share. AdaptHealth has set its FY 2025 guidance at EPS. Equities research analysts expect that AdaptHealth Corp. will post 0.88 EPS for the current year.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.